Picture of Lytix Biopharma AS logo

LYTIX Lytix Biopharma AS Cashflow Statement

0.000.00%
no flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapMomentum Trap

Annual cashflow statement for Lytix Biopharma AS, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
C2021
December 31st
C2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
NAS
NAS
NAS
NAS
NAS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-32.4-42.1-48.1-56.1-87.9
Depreciation
Non-Cash Items5.768.44.051.384.18
Other Non-Cash Items
Changes in Working Capital-10.29.34-1.041.15-13.2
Change in Accounts Receivable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities-36.8-24.3-44.6-52.6-96
Capital Expenditures0-0.154-0.049
Purchase of Fixed Assets
Other Investing Cash Flow Items00.138-49.229.8
Sale/Maturity of Investment
Change in Net Investments
Other Investing Cash Flow
Cash from Investing Activities00.138-49.429.7
Financing Cash Flow Items-11.5-0.055-0.003
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities-0.00540213-0.749-0.943
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-36.815.7169-103-67.2